BONE FRACTURE RECEIVING LH-RH AGONISTS FOR PROSTATIC CANCER

(Background) Luteinizing hormone-releasing hormone (LHRH) agonists are popullary used drugs in the treatment of prostatic cancer. However, it has been reported that continuation of a low testosterone level following a longterm administration of these drugs reduces the bone mineral density and makes...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nippon Hinyokika Gakkai zasshi 2000/06/20, Vol.91(6), pp.542-546
Hauptverfasser:	Hatano, Takashi, Igarashi, Hiroshi, Nakada, Jojiro, Oishi, Yukihiko, Yanada, Syuichi, Furuta, Akira, Takizawa, Akitoshi, Iwamuro, Shinya, Tashiro, Kazuya
Format:	Artikel
Sprache:	jpn
Schlagworte:	Aged Aged, 80 and over Antineoplastic Agents, Hormonal - adverse effects Bone Density bone fracture Fractures, Bone - chemically induced Fractures, Bone - diagnosis Gonadotropin-Releasing Hormone - agonists Goserelin - adverse effects Humans Leuprolide - adverse effects LHRH agonist Male Osteoporosis - chemically induced Osteoporosis - diagnosis prostatic cancer Prostatic Neoplasms - drug therapy Spine - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!